Amit V Khera

List of Publications by Citations

113 papers	10,772 citations	43 h-index	103 g-index
139 ext. papers	15,539 ext. citations	15 avg, IF	6.33 L-index

#	Paper	IF	Citations
113	Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. *New England Journal of Medicine*, **2011**, 364, 127-35	59.2	1403
112	Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. *Nature Genetics*, **2018**, 50, 1219-1224	36.3	1073
111	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*, **2019**, 140, e596-e646	16.7	898
110	Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. *New England Journal of Medicine*, **2016**, 375, 2349-2358	59.2	601
109	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology*, **2019**, 74, 1376-1414	15.1	463
108	Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. *Journal of the American College of Cardiology*, **2016**, 67, 2578-89	15.1	458
107	Monkeys pay per view: adaptive valuation of social images by rhesus macaques. *Current Biology*, **2005**, 15, 543-8	6.3	313
106	Exome-wide association study of plasma lipids in >300,000 individuals. *Nature Genetics*, **2017**, 49, 1758-1766	36.3	310
105	Genetics of coronary artery disease: discovery, biology and clinical translation. *Nature Reviews Genetics*, **2017**, 18, 331-344	30.1	267
104	Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood. *Cell*, **2019**, 177, 587-596.e9	36.2	265
103	Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. *Obesity*, **2013**, 21, E439-47	8	263
102	Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. *Nature Genetics*, **2018**, 50, 1514-1523	36.3	260
101	Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). *Circulation*, **2014**, 129, 635-42	16.7	244
100	A Genetic Variant Associated with Five Vascular Diseases Is a Distal Regulator of Endothelin-1 Gene Expression. *Cell*, **2017**, 170, 522-533.e15	56.2	236
99	Mendelian Randomization. *JAMA - Journal of the American Medical Association*, **2017**, 318, 1925-1926	27.4	234
98	ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. *Journal of the American College of Cardiology*, **2017**, 69, 2054-2063	15.1	226
97	A structural variation reference for medical and population genetics. *Nature*, **2020**, 581, 444-451	50.4	223

96	Genetic Association of Waist-to-Hip Ratio With Cardiometabolic Traits, Type 2 Diabetes, and Coronary Heart Disease. *JAMA - Journal of the American Medical Association*, **2017**, 317, 626-634	27.4	195
95	Genetic analysis in UK Biobank links insulin resistance and transendothelial migration pathways to coronary artery disease. *Nature Genetics*, **2017**, 49, 1392-1397	36.3	127
94	Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels. *Journal of the American College of Cardiology*, **2016**, 68, 2761-2772	15.1	127
93	Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). *Circulation*, **2017**, 135, 2494-2504	16.7	126
92	Whole-Genome Sequencing to Characterize Monogenic and Polygenic Contributions in Patients Hospitalized With Early-Onset Myocardial Infarction. *Circulation*, **2019**, 139, 1593-1602	16.7	112
91	Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease. *JAMA - Journal of the American Medical Association*, **2017**, 317, 937-946	27.4	109
90	The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. *Journal of the American College of Cardiology*, **2011**, 58, 2068-75	15.1	95
89	Effect of right ventricular function and venous congestion on cardiorenal interactions during the treatment of decompensated heart failure. *American Journal of Cardiology*, **2010**, 105, 511-6	3	93
88	Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. *Circulation*, **2009**, 119, 1711-9	16.7	92
87	Deep-coverage whole genome sequences and blood lipids among 16,324 individuals. *Nature Communications*, **2018**, 9, 3391	17.4	90
86	Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions. *Nature Communications*, **2020**, 11, 3635	17.4	88
85	Body fat distribution and incident cardiovascular disease in obese adults. *Journal of the American College of Cardiology*, **2015**, 65, 2150-1	15.1	80
84	Future therapeutic directions in reverse cholesterol transport. *Current Atherosclerosis Reports*, **2010**, 12, 73-81	6	79
83	Genetic inactivation of ANGPTL4 improves glucose homeostasis and is associated with reduced risk of diabetes. *Nature Communications*, **2018**, 9, 2252	17.4	71
82	Improving reporting standards for polygenic scores in risk prediction studies. *Nature*, **2021**, 591, 211-219	50.4	70
81	Dense genotyping of candidate gene loci identifies variants associated with high-density lipoprotein cholesterol. *Circulation: Cardiovascular Genetics*, **2011**, 4, 145-55		66
80	The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality. *Journal of the American College of Cardiology*, **2013**, 62, 1909-10	15.1	61
79	The novel atherosclerosis locus at 10q11 regulates plasma CXCL12 levels. *European Heart Journal*, **2011**, 32, 963-71	9.5	57

78	Race, socioeconomic deprivation, and hospitalization for COVID-19 in English participants of a national biobank. *International Journal for Equity in Health*, **2020**, 19, 114	4.6	56
77	Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease. *Nature Communications*, **2018**, 9, 1613	17.4	55
76	Accuracy of noninvasively determined pulmonary artery systolic pressure. *American Journal of Cardiology*, **2010**, 105, 1192-7	3	54
75	Phenotypic Consequences of a Genetic Predisposition to Enhanced Nitric Oxide Signaling. *Circulation*, **2018**, 137, 222-232	16.7	53
74	Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 1880-8	9.4	51
73	A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease. *PLoS Genetics*, **2020**, 16, e1008629	6	49
72	Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease. *Circulation Research*, **2017**, 121, 81-88	15.7	48
71	Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia. *American Journal of Cardiology*, **2015**, 115, 178-82	3	46
70	Anti-oxidative and cholesterol efflux capacities of high-density lipoprotein are reduced in ischaemic cardiomyopathy. *European Journal of Heart Failure*, **2013**, 15, 1215-9	12.3	42
69	Analysis of cardiac magnetic resonance imaging in 36,000 individuals yields genetic insights into dilated cardiomyopathy. *Nature Communications*, **2020**, 11, 2254	17.4	40
68	On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study). *American Journal of Cardiology*, **2010**, 106, 451-6	3	35
67	Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease. *Journal of the American College of Cardiology*, **2020**, 75, 2769-2780	15.1	33
66	Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2021**, 41, 465-474	9.4	32
65	Association of Rare Pathogenic DNA Variants for Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome, and Lynch Syndrome With Disease Risk in Adults According to Family History. *JAMA Network Open*, **2020**, 3, e203959	10.4	31
64	Rare Protein-Truncating Variants in APOB, Lower Low-Density Lipoprotein Cholesterol, and Protection Against Coronary Heart Disease. *Circulation Genomic and Precision Medicine*, **2019**, 12, e002376	5.2	30
63	Low coverage whole genome sequencing enables accurate assessment of common variants and calculation of genome-wide polygenic scores. *Genome Medicine*, **2019**, 11, 74	14.4	29
62	Is Coronary Atherosclerosis One Disease or Many? Setting Realistic Expectations for Precision Medicine. *Circulation*, **2017**, 135, 1005-1007	16.7	27
61	Monogenic and Polygenic Contributions to Atrial Fibrillation Risk: Results From a National Biobank. *Circulation Research*, **2020**, 126, 200-209	15.7	26

60	Potent peroxisome proliferator-activated receptor-δagonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome. *European Heart Journal*, **2015**, 36, 3020-2	9.5	24
59	The power of genetic diversity in genome-wide association studies of lipids. *Nature*, **2021**,	50.4	24
58	Genome-Wide Polygenic Score, Clinical Risk Factors, and Long-Term Trajectories of Coronary Artery Disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2020**, 40, 2738-2746	9.4	24
57	Race, Socioeconomic Deprivation, and Hospitalization for COVID-19 in English participants of a National Biobank **2020**,		23
56	Validation of a Genome-Wide Polygenic Score for Coronary Artery Disease in South Asians. *Journal of the American College of Cardiology*, **2020**, 76, 703-714	15.1	22
55	Heterozygous Gene Deficiency and Risk of Coronary Artery Disease. *Circulation Genomic and Precision Medicine*, **2020**, 13, 417-423	5.2	21
54	Association of Genetic Variation With Cirrhosis: A Multi-Trait Genome-Wide Association and Gene-Environment Interaction Study. *Gastroenterology*, **2021**, 160, 1620-1633.e13	13.3	20
53	Evaluation of the Pooled Cohort Equations for Prediction of Cardiovascular Risk in a Contemporary Prospective Cohort. *American Journal of Cardiology*, **2017**, 119, 881-885	3	18
52	Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease. *Diabetes*, **2017**, 66, 2310-2315	0.9	17
51	Rare Genetic Variants Associated With Sudden Cardiac Death in Adults. *Journal of the American College of Cardiology*, **2019**, 74, 2623-2634	15.1	17
50	Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics. *Trends in Cardiovascular Medicine*, **2009**, 19, 195-201	6.9	16
49	Genetic Association of Finger Photoplethysmography-Derived Arterial Stiffness Index With Blood Pressure and Coronary Artery Disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2019**, 39, 1253-1261	9.4	15
48	Polygenic basis and biomedical consequences of telomere length variation. *Nature Genetics*, **2021**, 53, 1425-1433	36.3	15
47	A single-cell atlas of human and mouse white adipose tissue.. *Nature*, **2022**,	50.4	15
46	Leveraging fine-mapping and non-European training data to improve cross-population polygenic risk scores		14
45	Genetic Risk, Lifestyle, and Coronary Artery Disease. *New England Journal of Medicine*, **2017**, 376, 1194-1	59.2	13
44	Performance of Atrial Fibrillation Risk Prediction Models in Over 4 Million Individuals. *Circulation: Arrhythmia and Electrophysiology*, **2021**, 14, e008997	6.4	13
43	DNA Sequence Variation in Encoding the Activin Receptor-Like Kinase 7 Influences Body Fat Distribution and Protects Against Type 2 Diabetes. *Diabetes*, **2019**, 68, 226-234	0.9	12

42	Leveraging Human Genetics to Estimate Clinical Risk Reductions Achievable by Inhibiting Factor XI. *Stroke*, **2019**, 50, 3004-3012	6.7	11
41	On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study). *American Journal of Cardiology*, **2015**, 116, 694-8	3	11
40	Volanesorsen, Familial Chylomicronemia Syndrome, and Thrombocytopenia. *New England Journal of Medicine*, **2019**, 381, 2582-2584	59.2	11
39	Quantifying and Understanding the Higher Risk of Atherosclerotic Cardiovascular Disease Among South Asian Individuals: Results From the UK Biobank Prospective Cohort Study. *Circulation*, **2021**, 144, 410-422	16.7	11
38	Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies. *European Heart Journal*, **2021**, 42, 3388-3403	9.5	11
37	Titin Truncating Variants in Adults Without Known Congestive Heart Failure. *Journal of the American College of Cardiology*, **2020**, 75, 1239-1241	15.1	10
36	Association of Habitual Alcohol Intake With Risk of Cardiovascular Disease.. *JAMA Network Open*, **2022**, 5, e223849	10.4	10
35	Management of low levels of high-density lipoprotein-cholesterol. *Circulation*, **2013**, 128, 72-8	16.7	8
34	Integrative analysis of the plasma proteome and polygenic risk of cardiometabolic diseases. *Nature Metabolism*, **2021**, 3, 1476-1483	14.6	6
33	Transethnic Transferability of a Genome-Wide Polygenic Score for Coronary Artery Disease. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003092	5.2	5
32	Genome-Wide Polygenic Score and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study. *Circulation Genomic and Precision Medicine*, **2020**, 13, e002767	5.2	5
31	The future of low-density lipoprotein cholesterol lowering therapy: An end to statin exceptionalism?. *European Journal of Preventive Cardiology*, **2016**, 23, 1062-4	3.9	5
30	Machine learning enables new insights into clinical significance of and genetic contributions to liver fat accumulation		5
29	Association of machine learning-derived measures of body fat distribution in >40,000 individuals with cardiometabolic diseases		5
28	Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants		5
27	A trans-ancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation		5
26	Fasting for lipid testing: Is it worth the trouble?. *Archives of Internal Medicine*, **2012**, 172, 1710-2		5
25	Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease. *Cell Reports Medicine*, **2021**, 2, 100437	18	4

24	Concordance of a High Polygenic Score Among Relatives: Implications for Genetic Counseling and Cascade Screening. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003262	5.2	4
23	Genetic Predictor to Identify Individuals With High Lipoprotein(a) Concentrations. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003182	5.2	4
22	Demystifying HDL Cholesterol-A "Human Knockout" to the Rescue?. *Clinical Chemistry*, **2017**, 63, 33-36	5.5	3
21	Selection of 51 predictors from 13,782 candidate multimodal features using machine learning improves coronary artery disease prediction.. *Patterns*, **2021**, 2, 100364	5.1	3
20	Randomized prospective evaluation of genome sequencing versus standard-of-care as a first molecular diagnostic test. *Genetics in Medicine*, **2021**, 23, 1689-1696	8.1	3
19	Leveraging fine-mapping and multipopulation training data to improve cross-population polygenic risk scores.. *Nature Genetics*, **2022**, 54, 450-458	36.3	3
18	Machine learning enables new insights into genetic contributions to liver fat accumulation.. *Cell Genomics*, **2021**, 1,		3
17	Response to letter regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)". *Circulation*, **2014**, 130, e152	16.7	2
16	South Asian Patient Population Genetics Reveal Strong Founder Effects and High Rates of Homozygosity New Resources for Precision Medicine		2
15	Inherited basis of visceral, abdominal subcutaneous and gluteofemoral fat depots		2
14	Rare, Damaging DNA Variants in and Risk of Coronary Artery Disease: Insights From Functional Genomics and Large-Scale Sequencing Analyses. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003399	5.2	2
13	Design and user experience testing of a polygenic score report: a qualitative study of prospective users. *BMC Medical Genomics*, **2021**, 14, 238	3.7	2
12	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. *Nature Genetics*,	36.3	2
11	A single cell atlas of human and mouse white adipose tissue		1
10	Genetic Predisposition to Abdominal Obesity and Cardiometabolic Risk-Reply. *JAMA - Journal of the American Medical Association*, **2017**, 317, 2334-2335	27.4	0
9	Genotyping in Anticoagulated Patients After Percutaneous Coronary Intervention: Should It Be Routine?. *Circulation*, **2022**, 145, 721-723	16.7	0
8	Association of the Interaction Between Familial Hypercholesterolemia Variants and Adherence to a Healthy Lifestyle With Risk of Coronary Artery Disease.. *JAMA Network Open*, **2022**, 5, e222687	10.4	0
7	Analyzing human knockouts to validate GPR151 as a therapeutic target for reduction of body mass index.. *PLoS Genetics*, **2022**, 18, e1010093	6	0

6	Estimated Yield of Screening for Heterozygous Familial Hypercholesterolemia With and Without Genetic Testing in US Adults.. *Journal of the American Heart Association*, **2022**, e025192	6	0
5	The potential of polygenic scores to improve cost and efficiency of clinical trials. *Nature Communications*, **2022**, 13,	17.4	0
4	My most famous patient. (Second-place essay at the Francis A. Velay Humanism in Medicine Essay Contest presented by the Arnold P. Gold Foundation). *Academic Medicine*, **2008**, 83, 1170-1	3.9	
3	Response by Patel and Khera to Letter Regarding Article, "Quantifying and Understanding the Higher Risk of Atherosclerotic Cardiovascular Disease Among South Asian Individuals: Results From the UK Biobank Prospective Cohort Study".. *Circulation*, **2022**, 145, e147-e148	16.7	
2	Perspectives on Identifying and Treating Familial Hypercholesterolemia in Childhood. *Clinical Chemistry*, **2021**, 67, 1312-1317	5.5	
1	Abdominal subcutaneous adipose tissue negatively associates with subclinical coronary artery disease in men with psoriasis. *American Journal of Preventive Cardiology*, **2021**, 8, 100231	1.9	